In this issue:
Phase 2 trial of ibudilast in patients with progressive MS
Extension study of oral amiselimod in RRMS
Treatment change in patients with silent new MRI lesions
Early vs late initiation of DMT
Cladribine vs fingolimod, natalizumab and betainterferon
Positive impact of cladribine on quality of life
Clinical activity after fingolimod cessation
Natalizumab during pregnancy and lactation
Efficacy and safety of natalizumab extended interval dosing
Baseline neurofilament levels and 10-year follow-up of MS patients
Please login below to download this issue (PDF)